Standard-dose radiation therapy is superior to high-dose RT in terms of OS and local-regional control in patients undergoing chemotherapy for stage III NSCLC, found research presented at ASCO 2013.
Imatinib is prolongs PFS but not OS compared to placebo among patients with imatinib- or sunitinib-refractory advanced GIST, according to data presented at ASCO 2013.
Idelalisib (GS-1101) is associated with rapid tumor response in some patients diagnosed with relapsed or treatment-resistant CLL, found research presented at ASCO 2013.
Elderly patients with metastatic pancreatic cancer have shorter OS and receive less chemotherapy, fewer agents compared to younger patients, found research presented at ASCO 2013.
NGS shows promise in identifying solid tumors harboring “actionable” genetic alterations that can be targeted for personalized therapy, according to study results presented at ASCO 2013.
Use of sequential paclitaxel followed by oral fluorinated pyrimidines results in a trend for better disease-free survival in locally advanced gastric cancer, found research presented at ASCO 2013.
African-American women have a high number of breast cancer-related gene mutations and require more access to screening, found results of a study presented at ASCO 2013.
Neither zoledronic acid nor strontium-89 improve OS among patients with castrate-refractory prostate cancer, but Sr89 improves cPFS, according to data presented at ASCO 2013.
For patients with chromosomal rearrangements of the of the ALK gene, crizotinib yields longer PFS and a higher response rate versus standard chemotherapy, found data presented at ASCO 2013.
A case of acquired resistance to crizotinib has been described in a patient with metastatic lung adenocarcinoma harboring a CD74-ROS1 rearrangement, according to research presented at ASCO 2013.
Please login or register first to view this content.
